Effect of drug treatment options on the mobility and expression of blaKPC.

OBJECTIVES Both transposition and increases in gene expression have been implicated in the success of KPC-producing pathogens, but the stimulus required for these phenomena are unknown. It is possible that exposure to antimicrobials during patient treatment increases bla(KPC) expression or induces Tn4401 transposition. The purpose of this study was to determine if exposure to carbapenems or other antimicrobial drug classes could stimulate expression of bla(KPC) or the in vitro transposition of Tn4401. METHODS Five KPC-producing clinical isolates were evaluated in this study. Gene expression of RNA from each isolate exposed to subinhibitory, MIC or suprainhibitory levels of antibiotics was evaluated using real-time RT-PCR. Southern blots were performed on plasmids from isolates exposed to subinhibitory levels of antibiotics. RESULTS There were subtle changes in bla(KPC) RNA expression following antibiotic exposure that were both strain and drug dependent. Multiple plasmids ranging from ~8 to >200 kb were observed for the Enterobacteriaceae isolates, whereas the Pseudomonas aeruginosa isolate had one ~55 kb plasmid. No changes in hybridization patterns or binding intensity for the bla(KPC) probe were observed after antibiotic exposure. CONCLUSIONS While the changes in bla(KPC) RNA expression are subtle, the different responses observed suggest both strain- and genera-specific variations in response to different antibiotic treatments.

[1]  L. Rice,et al.  The KQ Element, a Complex Genetic Region Conferring Transferable Resistance to Carbapenems, Aminoglycosides, and Fluoroquinolones in Klebsiella pneumoniae , 2008, Antimicrobial Agents and Chemotherapy.

[2]  M. Synnestvedt,et al.  Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae , 2009, Infection Control & Hospital Epidemiology.

[3]  N. Hanson,et al.  Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli. , 2012, The Journal of antimicrobial chemotherapy.

[4]  L. Danziger,et al.  Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[5]  F. Champlin,et al.  Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. , 1989, Journal of medical microbiology.

[6]  N. Hanson,et al.  Model System To Evaluate the Effect of ampD Mutations on AmpC-Mediated β-Lactam Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[7]  D. Bonner,et al.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus , 1993, Antimicrobial Agents and Chemotherapy.

[8]  D. Paterson "Collateral damage" from cephalosporin or quinolone antibiotic therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Goering,et al.  Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. , 2003, The Journal of antimicrobial chemotherapy.

[10]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[11]  G. Bierbaum,et al.  Influence of ciprofloxacin and vancomycin on mutation rate and transposition of IS256 in Staphylococcus aureus. , 2011, International journal of medical microbiology : IJMM.

[12]  Vincent H Tam,et al.  Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. , 2010, The Journal of antimicrobial chemotherapy.

[13]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[14]  Baha Abdalhamid,et al.  Escherichia coli: development of carbapenem resistance during therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Paterson,et al.  Antibiotic resistance—What’s dosing got to do with it? , 2008, Critical care medicine.

[16]  N. Hanson,et al.  blaKPC RNA Expression Correlates with Two Transcriptional Start Sites but Not Always with Gene Copy Number in Four Genera of Gram-Negative Pathogens , 2011, Antimicrobial Agents and Chemotherapy.

[17]  D. Clewell,et al.  Properties of erythromycin-inducible transposon Tn917 in Streptococcus faecalis , 1980, Journal of bacteriology.

[18]  R. Bonomo,et al.  Outcomes and Genetic Relatedness of Carbapenem-Resistant Enterobacteriaceae at Detroit Medical Center , 2011, Infection Control & Hospital Epidemiology.

[19]  Robert A. Bonomo,et al.  Genetic Factors Associated with Elevated Carbapenem Resistance in KPC-Producing Klebsiella pneumoniae , 2010, Antimicrobial Agents and Chemotherapy.

[20]  P. Coudron,et al.  Plasmid-Mediated Resistance to Expanded-Spectrum Cephalosporins among Enterobacter aerogenesStrains , 1998, Antimicrobial Agents and Chemotherapy.

[21]  M. Ferraro,et al.  Plasmid-Mediated Carbapenem-Hydrolyzing Enzyme KPC-2 in an Enterobacter sp , 2004, Antimicrobial Agents and Chemotherapy.

[22]  J. Collins,et al.  A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.

[23]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[24]  P. Nordmann,et al.  Functional Characterization of Tn4401, a Tn3-Based Transposon Involved in blaKPC Gene Mobilization , 2011, Antimicrobial Agents and Chemotherapy.

[25]  S. Pournaras,et al.  Characteristics of Meropenem Heteroresistance in Klebsiella pneumoniae Carbapenemase (KPC)-Producing Clinical Isolates of K. pneumoniae , 2010, Journal of Clinical Microbiology.

[26]  Y. Carmeli,et al.  Plasmid-Mediated Imipenem-Hydrolyzing Enzyme KPC-2 among Multiple Carbapenem-Resistant Escherichia coli Clones in Israel , 2006, Antimicrobial Agents and Chemotherapy.

[27]  N. Woodford,et al.  Phenotypic and Enzymatic Comparative Analysis of the Novel KPC Variant KPC-5 and Its Evolutionary Variants, KPC-2 and KPC-4 , 2008, Antimicrobial Agents and Chemotherapy.

[28]  G. Daikos,et al.  Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions , 2012, Clinical Microbiology Reviews.